After-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data
Werewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.
How this was made
The 30-second read
Why it matters
The article reports fresh, primary information on trial enrollments, upcoming pivotal studies, and commercial rollout plans, leading to notable price moves across several small‑cap biotech stocks.
Market read
Multiple small‑cap biotech stocks experienced sharp after‑hours gains driven by fresh trial and commercialisation news, indicating short‑term trading opportunities.
What to watch
Potential dilution from future financing rounds and regulatory hurdles for trial candidates.
Background
After‑hours trading often reflects immediate reaction to company‑specific news, especially in biotech where trial updates drive volatility.
Ticker impact
After-hours the stock surged 90% to $0.81 following news of ongoing Phase 1/1b trials of WTX-124 and enrollment in a Phase 1b/2 trial for WTX-330.
Potential further upside if trial data are released; watch for volatility.
Large after‑hours price jump on fresh trial enrollment news suggests traders may chase momentum.
GOVX rose 12.66% in after‑hours to $0.67 after confirming a Phase 3 GEO‑MVA immune‑bridging study will start next quarter.
Likely continued rally if trial initiation proceeds as planned.
Trial initiation news is material for a biotech with limited pipeline.
MODD gained 7.87% in after‑hours to $3.70 as it announced the first phase of commercialisation of its Pivot tubeless patch pump in five U.S. markets starting October 2026.
Further upside possible as rollout details emerge.
Commercialisation plans for a novel medical device can drive investor interest.
OVID rose nearly 7% after‑hours to $2.93, citing multiple upcoming clinical milestones for OV4071 and OV329, including a Phase 1 trial data timeline and a ketamine challenge study.
Potential upside if early data are positive; watch for volatility.
Biotech stocks often react to announced trial timelines.
BIVI climbed 4.84% in after‑hours to $1.95 as it highlighted a Phase 2 ADDRESS‑LC study for long‑COVID cognitive impairment with topline results expected late summer 2026.
Further gains possible if trial data are encouraging.
Long‑COVID is a high‑interest therapeutic area; trial updates can move the stock.
GLSI rose over 6% after‑hours to $16.27 after reporting a lock‑up extension for insiders and pre‑IPO investors to Jan 2027.
Limited impact; price may stabilize.
Lock‑up extensions are modest news for a late‑stage biotech.
Market effects
Biotech sector may see broader rally as multiple companies report trial progress.
U.S. biotech stocks gain momentum in after‑hours trading.
Limited to U.S. listed biotech firms; no immediate global macro effect.
Counterpoint
Price spikes may be short‑lived without concrete data releases; risk of pull‑back.
Key entities
- companyWerewolf Therapeutics
Biotech developing conditionally activated cancer therapeutics.
- companyGeoVax Labs
Vaccine platform company advancing GEO‑MVA and other candidates.
- companyModular Medical
Medical‑device maker launching a tubeless insulin pump.
- companyOvid Therapeutics
Biotech focusing on CNS disorders with pipeline OV4071/OV329.
- companyBioVie
Developer of Bezisterim for long‑COVID and Parkinson's.
